专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5468501A Article useful for administration of pharmacologically-active substances transdermally, orally or by means of implant 失效
标题翻译：用于透皮，口服或通过植入物施用药理活性物质的物品
公开(公告)号：US5468501A
公开(公告)日：1995-11-21
申请号：US385205
申请日：1995-02-08
申请人： Agis Kydonieus , Kishore R. Shah , Bret Berner
发明人： Agis Kydonieus , Kishore R. Shah , Bret Berner
IPC分类号： A61K9/70 , A61K31/21 , A61M31/00 , A61F13/00
CPC分类号： A61K9/7084 , A61K31/21 , A61M31/002
摘要： A device useful for administration of pharmacologically-active substances transdermally, orally, or by means of subdermal implant includes an impermeable backing layer, a plasticized polyvinyl chloride layer, and an adhesive layer, wherein the plasticized polyvinyl chloride layer includes from about 20 up to about 70% by weight of a polyvinyl chloride resin, from about 20 up to about 70% by weight of a plasticizer, and from about 0.5 up to about 35% by weight of a pharmacologically-active substance such as isosorbide dinitrate, nicotine, clonidine, guanfacine, indomethacin, nitroglycerin, and prostaglandin and optionally excipients.
摘要翻译：用于通过皮下，口服或通过皮下植入来施用药理活性物质的装置包括不渗透背衬层，塑化聚氯乙烯层和粘合剂层，其中增塑聚氯乙烯层包括约20至约约 70重量％的聚氯乙烯树脂，约20至约70重量％的增塑剂和约0.5至约35重量％的药理活性物质如硝酸异山梨酯，尼古丁，可乐定，胍法辛，吲哚美辛，硝酸甘油和前列腺素以及任选的赋形剂。

2. 发明授权

US4767808A Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant 失效
标题翻译：用于透皮，口服或通过植入物施用药理活性物质的制品
公开(公告)号：US4767808A
公开(公告)日：1988-08-30
申请号：US122862
申请日：1987-11-19
申请人： Agis Kydonieus , Kishore R. Shah , Bret Berner
发明人： Agis Kydonieus , Kishore R. Shah , Bret Berner
IPC分类号： A61K9/70 , A61K31/165 , A61K31/21 , A61K31/34 , A61K31/405 , A61K31/415 , A61K31/465 , A61K31/557 , A61M31/00 , A61K9/00
CPC分类号： A61K31/165 , A61K31/21 , A61K31/34 , A61K31/405 , A61K31/415 , A61K31/465 , A61K31/557 , A61K9/703 , A61K9/7084 , A61M31/002
摘要： Described is an article of manufacture useful for administration of pharmacologically-active substances, transdermally, orally or by means of subdermal implant comprising a solid vinyl plastisol layer for contacting a patient's tissue, internally or externally, the layer containing from about 20 up to about 70% by weight of a polyvinyl chloride resin or a polyvinyl chloride-polyvinyl acetate copolymer containing a minor proportion of vinyl acetate; from about 20-70% plasticizer composition; from about 0.5 up to 35% of a pharmacologically-active substance such as isosorbide dinitrate, nicotine, clonidine, guanfacine, indomethacin, glyceryl trinitrate and prostaglandin and optionally excipients. Also described is the novel plasticizer-polyvinyl chloride composition of matter comprising 1-dodecylhexahydro-2H-azepin-2-one and polyvinyl chloride resin taken together with a pharmacologically-active substance wherein the 1-dodecylhexahydro-2H-azepin-2-one not only acts as a plasticizer but also acts as a penetration enhancer (through tissue) for the pharmacologically-active substance.
摘要翻译：描述了可用于施用药理学活性物质，经皮，口服或通过皮下植入的制剂，其包括固体乙烯基增塑溶胶层，用于在内部或外部将患者组织接触含有约20至约70的层重量百分比的聚氯乙烯树脂或含有少量醋酸乙烯酯的聚氯乙烯 - 聚乙酸乙烯酯共聚物; 约20-70％的增塑剂组成; 约0.5至35％的药理学活性物质如硝酸异山梨酯，尼古丁，可乐定，胍法辛，吲哚美辛，三硝酸甘油酯和前列腺素以及任选的赋形剂。还描述了包含1-十二烷基六氢-2H-氮杂-2-酮和聚氯乙烯树脂与药理活性物质一起的物质的新型增塑剂 - 聚氯乙烯组合物，其中1-十二烷基六氢-2H-氮杂-2-酮不仅用作增塑剂，但也用作药理活性物质的渗透促进剂（通过组织）。

3. 再颁专利

USRE34089E Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant 失效
公开(公告)号：USRE34089E
公开(公告)日：1992-10-06
申请号：US554499
申请日：1990-07-19
申请人： Agis Kydonieus , Kishore R. Shah , Bret Berner
发明人： Agis Kydonieus , Kishore R. Shah , Bret Berner
IPC分类号： A61K9/70 , A61K31/165 , A61K31/21 , A61K31/34 , A61K31/405 , A61K31/415 , A61K31/465 , A61K31/557 , A61M31/00
CPC分类号： A61K31/165 , A61K31/21 , A61K31/34 , A61K31/405 , A61K31/415 , A61K31/465 , A61K31/557 , A61K9/703 , A61K9/7084 , A61M31/002
摘要： Described is an article of manufacture useful for administration of pharmacologically-active substances, transdermally, orally or by means of subdermal implant comprising a solid vinyl plastisol layer for contacting a patient's tissue, internally or externally, the layer containing from about 20 up to about 70% by weight of a polyvinyl chloride resin or a polyvinyl chloride-polyvinyl acetate copolymer containing a minor proportion of vinyl acetate; from about 20-70% plasticizer composition, from about 0.5 up to 35% of pharmacologically-active substance such as isosorbide dinitrate, nicotine, clonidine, guanfacine, indomethacin, glyceryl trinitrate and prostaglandin and optionally excipients. Also described is the novel plasticizer-polyvinyl chloride composition of matter comprising 1-dodecylhexahydro-2H-azepin-2-one and polyvinyl chloride resin taken together with a pharmacologically-active substance .[.whereint he.]. .Iadd.wherein the .Iaddend.1-dodecylhexahydro-2H-azepin-2-one not only acts as a plasticizer but also acts as a penetration enhancer (through tissue) for the pharmacologically-active substance.

4. 发明授权

US4758434A Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant 失效
标题翻译：用于透皮，口服或通过植入物施用药理活性物质的制品
公开(公告)号：US4758434A
公开(公告)日：1988-07-19
申请号：US847635
申请日：1986-04-03
申请人： Agis Kydonieus , Kishore R. Shah , Bret Berner
发明人： Agis Kydonieus , Kishore R. Shah , Bret Berner
IPC分类号： A61K9/70 , A61K31/21 , A61M31/00 , A61L15/03 , A61F13/00
CPC分类号： A61K9/703 , A61K31/21 , A61K9/7084 , A61M31/002
摘要： Described is an article of manufacture useful for administration of pharmacologically-active substances, transdermally, orally or by means of subdermal implant comprising a solid vinyl plastisol layer for contacting a patient's tissue, internally or externally, the layer containing from about 20 up to about 70% by weight of a polyvinyl chloride resin or a polyvinyl chloride-polyvinyl acetate copolymer containing a minor proportion of vinyl acetate; from about 20-70% plasticizer composition; from abotu 0.5 up to 35% of pharmacologically-active substance such as isosorbide dinitrate, nicotine, clonidine, guanfacine, indomethacin, glyceryl trinitrate and prostaglandin and optionally excipients. Also described is the novel plasticizer-polyvinyl chloride composition of matter comprising 1-dodecylhexahydro-2H-azepin-2-one and polyvinyl chloride resin taken together with a pharmacologically-active substance whereint he 1-dodecylhexahydro-2H-azepin-2-one not only acts as a plasticizer but also acts as a penetration enhancer (through tissue) for the pharmacologically-active substance.
摘要翻译：描述了可用于施用药理学活性物质，经皮，口服或通过皮下植入的制剂，其包括固体乙烯基增塑溶胶层，用于在内部或外部将患者组织接触含有约20至约70的层重量百分比的聚氯乙烯树脂或含有少量醋酸乙烯酯的聚氯乙烯 - 聚乙酸乙烯酯共聚物; 约20-70％的增塑剂组成; 来自abotu 0.5至35％的药理活性物质如硝酸异山梨酯，尼古丁，可乐定，胍法西林，吲哚美辛，三硝酸甘油酯和前列腺素以及任选的赋形剂。还描述了包含1-十二烷基六氢-2H-氮杂-2-酮和聚氯乙烯树脂与药物活性物质一起的新型增塑剂 - 聚氯乙烯组合物，其中1-十二烷基六氢-2H-氮杂-2-酮不包括仅用作增塑剂，但也用作药理活性物质的渗透促进剂（通过组织）。

5. 发明授权

US09017667B2 Dosage forms that facilitate rapid activation of barley protease zymogen 有权
标题翻译：促进大麦蛋白酶酶原快速活化的剂型
公开(公告)号：US09017667B2
公开(公告)日：2015-04-28
申请号：US13123219
申请日：2009-10-09
申请人： Bret Berner
发明人： Bret Berner
IPC分类号： A61K38/48 , A61K9/20 , A61K9/48 , A61K9/50 , C12N9/50 , A61K9/16
CPC分类号： A61K38/4873 , A61K9/1623 , A61K9/2013 , A61K9/2077 , A61K9/2095 , A61K9/4858 , A61K9/5042 , A61K9/5084 , C12N9/50
摘要： The therapeutic efficacy of zymogen proteins for oral administration is improved by including in the formulation one or more excipients that optimize pH and other reaction conditions for rapid activation of the zymogen shortly after ingestion.
摘要翻译：通过在制剂中包含一种或多种优化pH和其他反应条件以在摄入后不久快速激活酶原的赋形剂来改善酶原蛋白质用于口服给药的治疗功效。

6. 发明授权

US09000046B2 Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract 有权
标题翻译：胃酸滞留剂用于将阿坎酸延长释放到上消化道
公开(公告)号：US09000046B2
公开(公告)日：2015-04-07
申请号：US13247956
申请日：2011-09-28
申请人： Bret Berner , Cuiping Chen
发明人： Bret Berner , Cuiping Chen
IPC分类号： A61K31/16 , A61K9/22 , A61K9/26 , A61K31/185 , A61K9/00 , A61K9/20
CPC分类号： A61K9/0065 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K31/185 , A61K47/10
摘要： Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.
摘要翻译：描述了用于持续释放阿坎酸的胃滞留剂型，其可以允许急性和长期治疗包括酒精依赖性，耳鸣，睡眠呼吸暂停，帕金森病，左旋多巴诱导的帕金森氏症运动障碍的疾病的每日一次或两次疾病，阿尔茨海默病，亨廷顿舞蹈病，肌萎缩性侧索硬化，皮质扩张抑郁症，偏头痛，精神分裂症，焦虑症，迟发性运动障碍，痉挛性，多发性硬化，各种类型的疼痛或暴饮暴食。还描述了使用剂型和制备剂型的方法的治疗方法。

7. 发明申请

US20120077878A1 GASTRIC RETENTIVE DOSAGE FORMS FOR EXTENDED RELEASE OF ACAMPROSATE INTO THE UPPER GASTROINTESTINAL TRACT 有权
标题翻译：胃肠增强剂用于延长胃肠激素释放的胃肠道剂量
公开(公告)号：US20120077878A1
公开(公告)日：2012-03-29
申请号：US13247956
申请日：2011-09-28
申请人： Bret Berner , Cuiping Chen
发明人： Bret Berner , Cuiping Chen
IPC分类号： A61K31/185 , A61P25/32
CPC分类号： A61K9/0065 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K31/185 , A61K47/10
摘要： Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.
摘要翻译：描述了用于持续释放阿坎酸的胃滞留剂型，其可以允许急性和长期治疗包括酒精依赖性，耳鸣，睡眠呼吸暂停，帕金森病，左旋多巴诱导的帕金森氏症运动障碍的疾病的每日一次或两次疾病，阿尔茨海默病，亨廷顿舞蹈病，肌萎缩性侧索硬化，皮质扩张抑郁症，偏头痛，精神分裂症，焦虑症，迟发性运动障碍，痉挛性，多发性硬化，各种类型的疼痛或暴饮暴食。还描述了使用剂型和制备剂型的方法的治疗方法。

8. 发明申请

US20100034895A1 METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE 有权
标题翻译：使用GASTRIC保留的加巴酚丁剂量治疗方法
公开(公告)号：US20100034895A1
公开(公告)日：2010-02-11
申请号：US12563781
申请日：2009-09-21
申请人： Bret Berner , Sui Yuen Eddie Hou , Gloria M. Gusler
发明人： Bret Berner , Sui Yuen Eddie Hou , Gloria M. Gusler
IPC分类号： A61K9/14 , A61K31/195 , A61P25/00
CPC分类号： A61K9/2866 , A61K9/0004 , A61K9/0065 , A61K9/2031 , A61K9/2054 , A61K9/284 , A61K9/48 , A61K31/195 , A61K45/06 , A61M31/002
摘要： A method of treatment for epilepsy and other disease stasis described, which comprises delivery of gabapentin in a gastric retained dosage form.
摘要翻译：描述了治疗癫痫和其他疾病的方法，其包括在胃保留剂型中递送加巴喷丁。

9. 发明申请

US20050215872A1 Monitoring of physiological analytes 有权
公开(公告)号：US20050215872A1
公开(公告)日：2005-09-29
申请号：US10982166
申请日：2004-11-05
申请人： Bret Berner , Chia-Ming Chiang , Michael Garrison , Janan Jona , Russell Potts , Janet Tamada , Michael Tierney
发明人： Bret Berner , Chia-Ming Chiang , Michael Garrison , Janan Jona , Russell Potts , Janet Tamada , Michael Tierney
IPC分类号： G01N27/28 , A61B5/00 , A61B5/145 , A61B5/1477 , A61N1/30 , G01N27/327 , A61B5/05
CPC分类号： A61B5/1486 , A61B5/14532 , A61B5/150022 , A61B5/150091 , A61B5/157 , A61N1/30 , C12Q1/006
摘要： Methods and devices are provided for measuring the concentration of target chemical analytes present in a biological system. Device configuration and/or measurement techniques are employed in order to reduce the effect of interfering species on sensor sensitivity. One important application of the invention involves a method and device for monitoring blood glucose values.

10. 发明授权

US06488962B1 Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms 有权
标题翻译：片剂形状以增强可膨胀控释口服剂型的胃滞留
公开(公告)号：US06488962B1
公开(公告)日：2002-12-03
申请号：US09598061
申请日：2000-06-20
申请人： Bret Berner , Jenny Louie-Helm
发明人： Bret Berner , Jenny Louie-Helm
IPC分类号： A61K914
CPC分类号： A61K9/0065 , A61K9/2031 , A61K9/2072
摘要： The retention of oral drug dosage forms in the stomach is improved by using swellable dosage forms that are shaped in a manner that will prevent them from inadvertently passing through the pylorus as a result of being in a particular orientation. The planar projection of the shape is one that has two orthogonal axes of different lengths, the longer being short enough to permit easy swallowing prior to swelling while the shorter is long enough within one-half hour of swelling to prevent passage through the pylorus.
摘要翻译：口服药物剂型在胃中的保留通过使用可膨胀的剂型来改善，其可以以防止它们因特定方向而无意地穿过幽门的方式成型。形状的平面突起是具有不同长度的两个正交轴的平面突起，其长度足够短以允许在肿胀之前容易吞咽，而较短的时间足以在半小时内膨胀以防止通过幽门。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式